Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) |
Sep. 30, 2026 |
Dec. 31, 2025 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Schedule of Accrued Expenses and Other Current Liabilities [Abstract] | |||||||||||
| Accrued research and development expense | [1] | $ 1,741,083 | $ 1,754,083 | ||||||||
| Accrued directors and officers (owners) compensation | 1,373,491 | 1,358,293 | |||||||||
| Cash portion of the Lind Note repayments | [2] | 625,000 | 492,376 | ||||||||
| Accrued compensation and employee benefits | 15,559 | 86,744 | |||||||||
| Others | 778,839 | 470,133 | |||||||||
| Total | $ 4,533,972 | $ 4,161,629 | [3] | ||||||||
| |||||||||||